US footwear company Crocs has taken Mosaic Brands to court for allegedly selling shoes that “flagrantly” copy the look of its unique 13-hole slip-on foam clogs.
Leading Australian oil and gas producer Santos is accused of misleading the market by âgreenwashingâ its environmental credentials in a landmark shareholder-led lawsuit filed in the Federal Court.
A law firm is investigating a potential class action on behalf of pet owners whose dogs have died or fallen ill after consuming food contaminated with a known toxin.
National Australia Bank has been hit with a $18.5 million fine after admitting to allegations by ASIC that it failed to adequately disclose its adviser fees for five years.
In a recent decision, the Full Federal Court confirmed that a trade mark owner who merely authorises use of its trade mark cannot be subject to liability for direct trade mark infringement under section 120(1) of the Trade Marks Act, writes Shelston IP’s Kathy Mytton and Sean McManis.
Reforms by the Morrison government passed earlier this month weakening continuous disclosure obligations will spur corporate defendants to engage in “expensive interlocutory warfare” to shut down class actions right off the bat, and plaintiffs lawyers are waiting to see how the courts interpret the new laws to determine these early strike-out fights.
A judge overseeing a Papua New Guinean politicianâs defamation lawsuit has criticised Nineâs refusal to take down two allegedly defamatory articles ahead of a delayed trial, saying there was no reason to keep them online except for the publisherâs âpride or egoâ.
A judge has reopened the trial in Hells Angels’ trade mark case against Melbourne-based retailer Redbubble to hear allegations by the bikie gang that the online marketplace was still selling infringing products after the July hearing wrapped up.
The CFMEU has abandoned its landmark multi-million dollar class action against labour hire company Workpac following the High Court’s ruling that dashed the hopes of casual workers seeking leave entitlements.
Swiss pharmaceutical company Biogen is seeking a court order blocking an Australian generic drug manufacturer from selling a cheap multiple sclerosis drug it claims infringes its patent for medicine Tecfidera, a court has heard.